Tirzepatide Rules The Day On Lilly Earnings Call

Robust Sales In Diabetes And Obesity, Plus Good Data In NASH

Lilly reports better than 50% sequential sales growth for Mounjaro, while Zepbound’s early launch has brought in $176m. The company also unveiled positive Phase IIb data with tirzepatide in NASH.

Lilly office building
Lilly reports soaring sales for Mounjaro and Zepbound • Source: Shutterstock

Tirzepatide was virtually the exclusive focus of Eli Lilly and Company’s Q4 and full-year 2024 earnings call on 6 February as the company revealed significant growth for Mounjaro in type 2 diabetes, a strong launch for Zepbound in obesity and positive data from a Phase IIb study of tirzepatide in non-alcoholic steatohepatitis (NASH).

Analysts were enthusiastic about Lilly’s quarterly performance, which included 28% year-over-year sales growth for the quarter and 20% growth for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

Stock Watch: Pfizer Relights Q2 Earnings Season’s Fire

 
• By 

Pfizer showed how to come out on top with investors during earnings season. Post strong sales growth – and avoid mentioning tariffs, most favored nation pricing or Medicare modernization impacts.

Leo Keeps On Profitable Path With Solid H1 Sales Growth

 
• By 

The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By 

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

More from Business

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By 

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.